TY - JOUR
T1 - Well-Differentiated Papillary Mesothelioma of the Peritoneum
T2 - A Retrospective Study from the RENAPE Observational Registry
AU - Vogin, Guillaume
AU - Hettal, Liza
AU - Vignaud, Jean Michel
AU - Dartigues, Peggy
AU - Goere, Diane
AU - Ferron, Gwenaël
AU - Heyd, Bruno
AU - Bereder, Jean Marc
AU - Tuech, Jean Jacques
AU - Glehen, Olivier
AU - de Chaisemartin, Cécile
AU - Lherm, Yoann
AU - Villeneuve, Laurent
AU - Kepenekian, Vahan
AU - Marchal, Frédéric
AU - Abba, Julio
AU - Abboud, Karine
AU - Alyami, Mohammad
AU - Arvieux, Catherine
AU - Averous, Gerlinde
AU - Bakrin, Naoual
AU - Rejeb, Houda Ben
AU - Benzerdjeb, Nazim
AU - Berton-Rigaud, Isabelle
AU - Bibeau, Frédéric
AU - Bonnefoy, Isabelle
AU - Bouzard, Dominique
AU - Brigand, Cécile
AU - Carrère, Sébastien
AU - Chevallier, Anne
AU - Cloud, Virginie
AU - Courvoisier, Thomas
AU - Delhorme, Jean Baptiste
AU - Dohan, Anthony
AU - Dumont, Frédéric
AU - Eveno, Clarisse
AU - Fontaine, Juliette
AU - Gagniere, Johan
AU - Ghouti, Laurent
AU - Gilly, François Noël
AU - Gladieff, Laurence
AU - Guilloit, Jean Marc
AU - Guyon, Frédéric
AU - Isaac, Sylvie
AU - Jourdan-Enfer, Peggy
AU - Kaci, Rachid
AU - Kianmanesh, Reza
AU - Laverrière, Marie Hélène
AU - Lelong, Bernard
AU - Leroux-Broussier, Agnès
AU - the RENAPE Network
N1 - Publisher Copyright:
© 2019, Society of Surgical Oncology.
PY - 2019/3/15
Y1 - 2019/3/15
N2 - Background: Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare entity. Questions regarding management are still being debated as no more than 50 cases have been reported in the literature. Objective: We aimed to analyze the clinical, therapeutic, and prognostic data of patients with WDPMP from the RENAPE observational registry. Patients and Methods: All patients diagnosed with WDPMP and prospectively included in the RENAPE national registry between 2010 and 2018 were also included in our study. Expert pathologists from the RENA-PATH group confirmed all cases. All clinical, therapeutic, postoperative, and prognostic data were extracted and analyzed. Results: We report on 56 patients with a mean age of 52 years (range 21–74). WDPMP was incidentally diagnosed during imaging or surgery in 16% and 36% of patients, respectively, and an association with synchronous malignancy was found in 18% of patients. Nine lesions showed discrete signs of fatty invasion. The median Peritoneal Cancer Index was 11 (range 0–33). Eleven patients were treated with definitive excision, 4 were treated with cytoreductive surgery (CRS) only, 37 were treated with CRS and hyperthermic intraperitoneal chemotherapy (HIPEC), and 2 were treated with CRS plus HIPEC plus early postoperative intraperitoneal chemotherapy. CRS was considered to be complete in 90% of cases. One patient died postoperatively and 16 patients (31%) faced postoperative complications. The median disease-free survival was 144 months; Four patients relapsed, with a median period of 27 months. No prognostic factors could be identified. Conclusions: Our analysis confirms the favorable prognosis of WDPMP. CRS and HIPEC could be a therapeutic option for diffuse, symptomatic, and/or recurrent disease.
AB - Background: Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare entity. Questions regarding management are still being debated as no more than 50 cases have been reported in the literature. Objective: We aimed to analyze the clinical, therapeutic, and prognostic data of patients with WDPMP from the RENAPE observational registry. Patients and Methods: All patients diagnosed with WDPMP and prospectively included in the RENAPE national registry between 2010 and 2018 were also included in our study. Expert pathologists from the RENA-PATH group confirmed all cases. All clinical, therapeutic, postoperative, and prognostic data were extracted and analyzed. Results: We report on 56 patients with a mean age of 52 years (range 21–74). WDPMP was incidentally diagnosed during imaging or surgery in 16% and 36% of patients, respectively, and an association with synchronous malignancy was found in 18% of patients. Nine lesions showed discrete signs of fatty invasion. The median Peritoneal Cancer Index was 11 (range 0–33). Eleven patients were treated with definitive excision, 4 were treated with cytoreductive surgery (CRS) only, 37 were treated with CRS and hyperthermic intraperitoneal chemotherapy (HIPEC), and 2 were treated with CRS plus HIPEC plus early postoperative intraperitoneal chemotherapy. CRS was considered to be complete in 90% of cases. One patient died postoperatively and 16 patients (31%) faced postoperative complications. The median disease-free survival was 144 months; Four patients relapsed, with a median period of 27 months. No prognostic factors could be identified. Conclusions: Our analysis confirms the favorable prognosis of WDPMP. CRS and HIPEC could be a therapeutic option for diffuse, symptomatic, and/or recurrent disease.
UR - http://www.scopus.com/inward/record.url?scp=85059891110&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-07153-2
DO - 10.1245/s10434-018-07153-2
M3 - Article
C2 - 30635798
AN - SCOPUS:85059891110
SN - 1068-9265
VL - 26
SP - 852
EP - 860
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 3
ER -